HHS Secretary Robert F. Kennedy Jr. Seeks to Ease Restrictions on Certain Peptides

Health and Human Services Secretary Robert F. , aged 72, has expressed support for easing restrictions on certain peptides. He stated that he is a "big fan of peptides" and has observed positive effects from using them for injury recovery.

Peptides are short chains of amino acids that regulate functions such as metabolism, tissue repair, and immune response. The body naturally produces peptides like collagen and oxytocin. Synthetic versions include compounds such as Ozempic and aspartame.

Since 2023, the Food and Drug Administration has reclassified 19 synthetic peptides as Category 2 Bulk Drug Substances, which limits compounding pharmacies from producing them due to concerns over safety and quality.

Potential Reclassification of Specific Peptides Secretary Robert F.

Kennedy Jr. is pushing to reclassify 14 of these peptides back to Category 1, enabling licensed compounding pharmacies to make them available for patients. " He indicated that an announcement on new actions could occur within a couple of weeks.

An HHS spokesperson did not respond to a request for comment. The specific 14 peptides under consideration were not named by HHS representatives, though certain ones are commonly discussed in this context. Peptides assist with wound healing, muscle building, and cell signaling.

Patients use injectable forms for weight loss, skin improvement, and better sleep. Compared to small-molecule drugs, peptides can be delivered more precisely with potentially fewer side effects.

Physician Experiences and Benefits Dr.

Lisa Cassileth, a board-certified plastic and reconstructive surgeon and founder and CEO of The Practice Healthcare in Beverly Hills, has used peptides such as BPC-157, TB-500, and GHK-Cu in postoperative patients for about five years. She reported that patients experience faster recovery and additional benefits, including improvements in gastrointestinal symptoms, skin sensitivity, and chronic musculoskeletal issues.

Dr.

She stated that growth hormone-related peptides can help with anti-aging and maintaining body composition when used under medical supervision. BPC-157 has shown potential for tissue repair, stomach ulcer healing, and neuroprotection.

Insulin, a naturally occurring peptide, is sold synthetically to regulate blood glucose levels.

Safety Concerns and Regulatory Issues The FDA's reclassification has not reduced demand for these peptides.

Instead, it has led to a market of products labeled for "research use only," which avoids regulatory oversight. This results in uncertain product quality, possible contamination, and risks such as infections, hormone disruption, and skin changes. Dr.

Sue Decotiis stated that there is no clear evidence that the peptides are inherently dangerous when used appropriately. She noted that the main concerns involve sourcing, prescription, and usage, with poor manufacturing or unsupervised use increasing risks significantly. She recommended large-scale, long-term clinical studies to assess safety profiles, dosing, and effects.

Dr. Lisa Cassileth called for more robust studies and long-term evaluation of growth hormone secretagogues like ipamorelin. She explained that growth hormone can accelerate tumor growth and is not recommended for long-term use, and data on secretagogues' safety for extended dosing is needed.

FDA Approval and Future Access Easing restrictions would not equate to full FDA approval for these peptides.

Most peptides lack FDA approval, partly because many, like insulin and BPC-157, occur naturally and are difficult to patent. Without patents, pharmaceutical companies have little incentive to fund the costly clinical trials required for approval. Dr.

Sue Decotiis said that many peptides are unlikely to receive FDA approval, not due to safety issues, but because producers cannot afford the extensive studies. Dr. Lisa Cassileth indicated that reclassification would integrate peptides into mainstream medical practice, encouraging physician education, research funding, and clinical acceptance.

She added that formal clearance would make physicians more comfortable using these compounds in a safe, structured, and evidence-based manner.

Guidance for Peptide Use Many peptides are currently available through licensed 503A compounding pharmacies under state oversight, producing sterile, regulated products.

However, access varies by state based on regulatory interpretations. Dr. Lisa Cassileth advised sourcing peptides from licensed pharmacies and obtaining prescriptions from qualified clinicians who understand indications, dosing, and risks.

Self-diagnosis and treatment should be avoided. Dr. Sue Decotiis warned that even safe peptides can mask underlying conditions if not part of a structured, individualized treatment plan. Proper medical oversight is essential for safe and effective outcomes.